Scientists Take Big Step Toward Stopping Cancer Metastasis

New research uncovers how levels of a key protein can spark cancer spread

Article ID: 689248

Released: 8-Feb-2018 12:05 PM EST

Source Newsroom: Scripps Research Institute

  • Credit: Elena Deryugina and James P. Quigley

    Left: The robust network of fully dilated, angiogenic blood vessels (red) within a primary tumor, which developed from LTBP3-competent epidermoid carcinoma cells (green). Right: In contrast, the LTBP3-deficient tumors develop thinner, collapsed vessels, which are incapable of efficiently supporting cancer cell dissemination.

  • Credit: Elena Deryugina and James P. Quigley

    This curve shows a dramatic difference in survival between head and neck cancer patients with high LTBP3 expression levels (green) and low expression levels (blue). Researchers believe LTBP3 levels, detectable before cancer reaches stage 4, may be an indicator of patient outcomes in this particular cancer type.

Newswise — LA JOLLA, CA – Feb. 7, 2018 – New research from The Scripps Research Institute (TSRI) may give scientists a chance to target tumors before they metastasize. The study, published recently in the Nature research journal Oncogene, shows that a protein called LTBP3 fuels a chain reaction that leads some early developing tumors to grow new blood vessels. These vessels then act like highways to spread cancer cells throughout the body, seeding metastatic tumors very early on.

“Lower LTBP3 levels appear to be associated with better prognosis in patients with certain types of cancer,” says Elena Deryugina, PhD, an assistant professor at TSRI and first author of the new study. Deryugina led the collaborative study with senior authors James P. Quigley, PhD, a TSRI professor, and Daniel Rifkin, PhD, a professor at NYU School of Medicine.

Their research addresses a long-standing challenge in medicine. Over the years, a potent growth factor molecule called TGFβ has caught the eye of many cancer researchers. TGFβ has multiple roles in healthy people and in disease, and it can be both a promoter and suppresser of tumor cell growth. Although TGFβ has been a tempting cancer therapy target for a long time, scientists still do not know know how to dampen its harmful effects without interfering with its normal roles in the body.

As long-time collaborators, Deryugina and Quigley have led research that shows that the initial steps of tumor metastasis can occur when a primary tumor is barely detectable. This work sparked their interest in the role of LTBP3, short for Latent TGFβ Binding Protein 3. They knew that LTBP3 partners with TGFβ to regulate its secretion, activation and maturation, but wondered what else LTBP3 might control.

Could LTBP3 set TGFβ on its harmful path of action in early-stage tumors, and might LTBP3 have its own role, independent of TGFβ, in cancer metastasis?

Researchers used chick embryo tumor models and a rodent model of head and neck cancer to discover how LTBP3 is involved in the spread of aggressive tumor cells. They knocked down LTBP3 expression and secretion in human tumor cell lines representing carcinoma, head and neck carcinoma and a fibrosarcoma. In each model, the team found that without LTBP3, primary tumor cells could not metastasize efficiently.

“Our experimental findings showed that LTBP3 is active in the very early steps of metastatic spread,” says Quigley.

“Specifically, LTBP3 appears to help tumors grow new blood vessels in a process called angiogenesis, which is critical for tumor cell intravasation. That is when cancer cells enter into blood vessels of defined size and permeability,” adds Deryugina. 

Importantly, the new data is in line with clinical findings that LTBP3 levels can indicate better overall survival in cancer patients with early-stage head and neck carcinomas.

Taken together, these findings suggest LTBP3 may be a good “upstream” drug target to treat early stage tumors without affecting more complex roles of TGFβ in other parts of the body.

Researchers next plan to investigate precisely how LTBP3 and TGFβ biochemically partner in the induction of new blood vessels deep within a tumor.

Additional authors of the study, “LTBP3 promotes early metastatic events during cancer cell dissemination,” were Ewa Zajac, PhD, and Tomoki Muramatsu, PhD, of The Scripps Research Institute; and Lior Zilberberg, PhD, Grishma Joshi, PhD, and Branka Dabovic, PhD, of the New York University School of Medicine.

The study was supported by the National Institutes of Health grants R01CA157792 (ED), R01CA105412 (JQ) and R01CA034282 (DR).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.

SEE ORIGINAL STUDY


Comment/Share

Chat now!